The FDA accelerated the approval for pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive gastric or GEJ adenocarcinoma based on the ORR in the first analysis of KEYNOTE-811. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.